Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis

British Journal of Dermatology

Volumn 177, Issue 1, 2017, Pages 188-196

  Chasset, F ^a   Bouaziz, J D ^b   Costedoat Chalumeau, N ^c,d   Frances C ^a   Arnaud, L ^e  

^a HÔPITAL TENON   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d Hôpital Cochin ^*  (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; MEPACRINE; ANTIMALARIAL AGENT; DERMATOLOGICAL AGENT;

ARTICLE; CHILBLAIN; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DRUG TREATMENT FAILURE; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN LUPUS ERYTHEMATOSUS; SYSTEMATIC REVIEW; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; CHLOROQUINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85018368110     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15312     Document Type: Article

References (53)

1. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113–24.
2. Merola JF, Nyberg F, Furukawa F, et al. Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. Lupus Sci Med 2015; 2:e000085.
3. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014; 48–49:14–9.
4. Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol 2016; 17:135–46.
5. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011; 65:e179–93.
6. Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009; 18:735–9.
7. Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis 2012; 15:62–8.
8. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012; 166:616–23.
9. Fennira F, Chasset F, Soubrier M, et al. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. J Am Acad Dermatol 2016; 74:1248–51.
10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25:603–5.
11. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration, 2011; chapter 8.
12. Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord 2001; 12:232–6.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1–12.
14. Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011; 147:203–8.
15. Barendregt JJ, Doi SA, Lee YY et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013; 67:974–8.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–88.
17. Kraak JH, Van Ketel W, Prakken JR, Van Zwet W. The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica 1965; 130:293–305.
18. Tuffanelli DL. Lupus erythematosus panniculitis (profundus). Arch Dermatol 1971; 103:231–42.
19. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol 1978; 98:497–506.
20. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118:412–6.
21. Spann CR, Callen JP, Klein JB, Kulick KB. Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. J Rheumatol 1988; 15:256–61.
22. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513–8.
23. Le Bozec P, La Guyadec T, Crickx B et al. [Chronic lupus erythematosus in lupus disease. Retrospective study of 136 patients]. Presse Med 1994; 23:1598–602 (in French).
24. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716–9.
25. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus – a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136:1033–41.
26. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983–7.
27. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C. [Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases]. Presse Med 2000; 29:1596–9 (in French).
28. Lardet D, Martin S, Truchetet F et al. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study]. Rev Med Interne 2004; 25:786–91.
29. Chieregato C, Barba A, Zini A, et al. Discoid lupus erythematosus: clinical and pathological study of 24 patients. J Eur Acad Dermatol Venereol 2004; 18:113.
30. Choonhakarn C, Poonsriaram A, Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol 2004; 43:815–8.
31. Bezerra ELM, Vilar MJP, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:3073–8.
32. Jacyk WK, Bhana KN. Lupus erythematosus profundus in black South Africans. Int J Dermatol 2006; 45:717–21.
33. Bouaziz JD, Barete S, Le Pelletier F, et al. Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. Lupus 2007; 16:163–7.
34. Kreuter A, Gaifullina R, Tigges C, et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145:244–8.
35. Cozzani E, Christana K, Rongioletti F, et al. Lupus erythematosus tumidus: clinical, histopathological and serological aspects and therapy response of 21 patients. Eur J Dermatol 2010; 20:797–801.
36. Mahfoudh A, Khaled A, Chtourou O, et al. [Chronic lupus erythematosus: 104 Tunisian cases]. Tunis Med 2010; 88:742–5 (in French).
37. Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 2011; 131:1981–6.
38. Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148:479–84.
39. Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261–7.
40. Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148:317–22.
41. Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol 2012; 39:531–5.
42. Yokogawa N, Tanikawa A, Amagai M, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol 2013; 23:318–22.
43. Momose Y, Arai S, Eto H, et al. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus. J Dermatol 2013; 40:94–7.
44. Kuhn A, Sigges J, Biazar C, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol 2014; 171:571–9.
45. Rodriguez-Caruncho C, Bielsa I, Fernández-Figueras MT, et al. Lupus erythematosus tumidus: a clinical and histological study of 25 cases. Lupus 2015; 24:751–5.
46. Yokogawa N, Takahashi T, Sato T, Yokota N. A double-blind, randomized, parallel-group study of hydroxychloroquine on cutaneous lupus erythematosus in Japan. Arthritis Rheum 2015; 67 (Suppl. 10): abstr. 1782.
47. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
48. Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189:425–7.
49. Lipsker D, Piette JC, Cacoub P, et al. Chloroquine–quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257–8.
50. Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12:444–54.
51. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015; 72:634–9.
52. Chasset F, Arnaud L, Costedoat-Chalumeau N, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol 2016; 74:693–9.
53. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20–8.